[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Advertisement

Springer Nature Link
Log in

Prognostic significance of NANOG and KLF4 for breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Some of the induced pluripotent stem cell (iPS cell)-inducing factors have been reported to be expressed in breast cancer. The aim of the present study was to examine the relationship between the expression of iPS cell-inducing factors and the prognosis of breast cancer patients.

Methods

In 100 breast cancer patients, the expression of c-MYC, KLF4, NANOG, OCT4, and SOX2 was determined by immunohistochemistry using a tissue microarray analysis.

Results

Patients with strong expression of NANOG had significantly lower disease-free survival (DFS) and overall survival rates than those with weak expression of NANOG (P = 0.004 and 0.033, respectively). In contrast, patients with strong expression of KLF4 had better DFS (P = 0.014).

Conclusions

Strong expression of NANOG is an indicator of a poor prognosis for breast cancer patients, whereas KLF4 is a favorable prognostic indicator. Our results suggest that NANOG stimulates the growth and metastasis of breast cancer cells, whereas KLF4 inhibits these processes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.

    Article  CAS  PubMed  Google Scholar 

  2. Yu J, Vodyanik MA, Smuga OK, Antosiewicz BJ, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–20.

    Article  CAS  PubMed  Google Scholar 

  3. Monsef N, Soller M, Isaksson M, Abrahamsson PA, Panagopoulos I. The expression of pluripotency marker Oct3/4 in prostate cancer and benign prostate hyperplasia. Prostate. 2009;69:909–16.

    Article  CAS  PubMed  Google Scholar 

  4. Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 2008;9:625–35.

    Article  Google Scholar 

  5. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2008;280:24731–7.

    Article  Google Scholar 

  6. Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet. 2010;20:91–5.

    Article  CAS  Google Scholar 

  7. Evans PM, Liu C. Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin. 2008;7:554–64.

    Article  Google Scholar 

  8. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer. 2005;104:2255–65.

    Article  CAS  PubMed  Google Scholar 

  9. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer. 2000;83:1688–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004;10:4314–24.

    Article  CAS  PubMed  Google Scholar 

  11. Yamanaka S. Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci. 2008;363:2079–87.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Jeter CR, Liu B, Liu X, Chen X, Liu C, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011;30:3833–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Leis O, Eguiara A, Arribillaga EL, Alberdi MJ, Garcia SH, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31:1354–65.

    Google Scholar 

  14. Naderi A, Weschendorff AE, Barbosa-Morais NL. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2007;26:1507–16.

    Article  CAS  PubMed  Google Scholar 

  15. Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie SH, Murayama A, et al. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha. Oncogene. 2009;28:2894–902.

    Article  CAS  PubMed  Google Scholar 

  16. Al-Haji M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.

    Article  Google Scholar 

  17. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–11.

    Article  CAS  PubMed  Google Scholar 

  18. Cai GL, Ying L, Bin BW, Yan JZ, Rui SZ, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253:1165–71.

    Article  Google Scholar 

Download references

Acknowledgments

We are grateful to Dr. T. Hori for the valuable technical assistance. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Surgery and Science, Graduate School of Research Into Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama, Japan

    Takuya Nagata, Yutaka Shimada, Shinichi Sekine, Ryota Hori, Koshi Matsui, Tomoyuki Okumura, Shigeaki Sawada & Kazuhiro Tsukada

  2. Department of Pathology, Graduate School of Research Into Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama, Japan

    Junya Fukuoka

Authors
  1. Takuya Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinichi Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryota Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koshi Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoyuki Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shigeaki Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junya Fukuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuhiro Tsukada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuya Nagata.

About this article

Cite this article

Nagata, T., Shimada, Y., Sekine, S. et al. Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer 21, 96–101 (2014). https://doi.org/10.1007/s12282-012-0357-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-012-0357-y

Keywords

Search

Navigation